Clementia
1 known investors
Ipsen is a biopharmaceutical group that publishes financial, legal, and non-financial reporting for shareholders, investors, and the public through documents such as its Universal Registration Document. The page is the investor reports and accounts section of the company's corporate site.
BiotechHealthtech
Investors · 1
Acquisitions · 2
Early investors' stakes continue via these dealsImCheck Therapeutics
Developer of antibody therapeutics targeting butyrophilin checkpoint molecules for cancer; acquired by Ipsen in 2025.
Memo Therapeutics
European biotech developing first-in-class antibody potravitug; agreed to be acquired by Ipsen for over €700 million.
In the news
Frequently asked questions
- What does Clementia do?
- Ipsen is a biopharmaceutical group that publishes financial, legal, and non-financial reporting for shareholders, investors, and the public through documents such as its Universal Registration Document. The page is the investor reports and accounts section of the company's corporate site.
- Who are Clementia's investors?
- Clementia's investors include Ysios Capital.